SAI Life Sciences Limited
NSE: SAILIFE · Pharmaceuticals · sector
₹1,445.30NSE close 2026-10-26
Key numbers
Market cap₹30,682 cr
Price₹1,445.30
52w high / low₹1,697 / ₹784
P/E84.2xSector median 27.9x
P/B12.3xSector median 2.9x
Book value₹117.0
Dividend yield–Sector median 0.48%
ROE15.7%Sector median 11.7%
ROCE20.1%Sector median 12.3%
OPM28.9%Sector median 14.0%
Debt / equity0.04xSector median 0.16x
EV/EBITDA47.1xSector median 18.6x
Interest cover15.0x
Current ratio1.69x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹158 cr vs borrowings ₹95 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 15.0x in the last 12 months.
- No promoter shares are pledged.
- Other income was 12% of net profit in the last 12 months.
- No dividend in the last 2 financial years.
- Price ₹1,445.30 on 2026-10-26: -14.8% from the 52-week high, +84.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,675.40 · low ₹640.25
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| EBITDA | 120 | 158 | 121 | 146 | 180 | 177 | 148 |
| OPM % | 27.2% | 27.2% | 24.4% | 27.1% | 32.3% | 29.4% | 26.7% |
| Other income | 9 | 10 | 10 | 15 | 8 | 16 | 4 |
| Net profit | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| EPS (₹) | 2.89 | 4.24 | 2.90 | 4.01 | 4.77 | 4.93 | 3.46 |
| Revenue YoY | +26.5% | +3.9% | +11.7% | ||||
| Profit YoY | +86.4% | +18.1% | +21.2% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY25 | FY26 | TTM |
|---|---|---|---|
| Revenue | 1,695 | 2,192 | 2,250 |
| EBITDA | 406 | 623 | 650 |
| Net profit | 170 | 349 | 362 |
| EPS (₹) | 8.83 | 16.63 | 17.17 |
| Revenue growth | +29.4% | – | |
| Profit growth | +105.1% | – | |
| Dividend / share (₹) | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | +58.2% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 2,128 | 2,484 |
| Borrowings | 129 | 95 |
| Cash & equivalents | 464 | 158 |
| Total assets | 3,160 | 3,626 |
| Fixed assets | 1,477 | 1,809 |
| Capital work in progress | 124 | 270 |
| Investments | 2 | 4 |
| Receivables | 355 | 374 |
| Inventory | 119 | 151 |
| Payables | 323 | 285 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 314 | 509 |
| Cash from investing | -537 | -395 |
| Cash from financing | 301 | -124 |
| Capex | 369 | 593 |
| Free cash flow | -55 | -84 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 8.0% | 14.0% |
| ROCE % | 13.5% | 19.6% |
| Debtor days | 76 | 62 |
| Inventory days | 93 | 97 |
| Payable days | 253 | 182 |
| Cash conversion cycle (days) | -84 | -23 |
| Working capital days | 166 | 96 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 34.50% |
| FIIs | 19.91% |
| DIIs | 32.32% |
| of which Mutual funds | 29.56% |
| of which Insurance | 2.65% |
| Government | 0.00% |
| Public (non-institutions) | 13.26% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 35.24% | 35.17% | 35.15% | 34.94% | 34.70% | 34.61% | 34.53% | 34.50% |
| Promoter group | % |
|---|---|
| MYTREYI KANUMURI Partner of Marigold Partners (Partnership Firm) | 10.44% |
| RANGA RAJU KANUMURI Partner of Sunflower Partners (Partnership Firm) | 7.34% |
| Gokaraju Subba Raju | 4.54% |
| MYTREYI KANUMURI Partner of Tulip Partners (Partnership Firm) | 4.37% |
| RANGA RAJU KANUMURI Partner of Lily Partners (Partnership Firm) | 3.25% |
| SAI Quest SYN Private Limited | 2.16% |
| Krishnam Raju Kanumuri | 1.42% |
| Gokaraju Lakshmi Tanuja | 0.63% |
| Sudha Kanumuri | 0.24% |
| Ranga Raju Kanumuri | 0.08% |
| Mytreyi Kanumuri | 0.03% |
| Continental Wines P Ltd | 0.01% |
| Bapi Raju Kanumuri | 0.00% |
| Kunaparaju Padmavathi | 0.00% |
| Prathima Kanumuri | 0.00% |
| Public holders above 1% | % |
|---|---|
| Invesco India Flexi CAP Fund | 7.43% |
| Nippon Life India Trustee Ltd-a/c Nippon India MUL | 6.79% |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual F | 3.19% |
| Aditya Birla SUN Life Mutual Fund - Aditya Birla S | 2.81% |
| Smallcap World Fund, INC | 2.57% |
| HSBC Mutual Fund - HSBC Aggressive Hybrid Fund | 1.86% |
| Axis MAX Life Insurance Limited A/C - Ulif00525/11 | 1.52% |
| Goldman Sachs Funds - Goldman Sachs India Equity P | 1.18% |
1,43,124 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SAILIFE | ₹30,682 cr | 84.2x | 12.3x | 15.7% | 20.1% | 28.9% | – | – |
Documents
- Annual report FY26
- Annual report FY25
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Contract Research, Development, and Manufacturing Services: Integrated services spanning discovery, development and commercial manufacturing of pharmaceutical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SAILIFE |
| BSE code | 544306 |
| ISIN | INE570L01029 |
| Face value | ₹1.0 |
| Incorporated | 1999-09-25 |
| Website | www.sailife.com |
| Plants (India / abroad) | 4 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.